Hutchison China MediTech Ltd ADR Stock
The Hutchison China MediTech Ltd ADR price is unchanged compared to yesterday.
Currently there is a rather positive sentiment for Hutchison China MediTech Ltd ADR with 4 Buy predictions and 1 Sell predictions.
As a result the target price of 17 € shows a positive potential of 39.34% compared to the current price of 12.2 € for Hutchison China MediTech Ltd ADR.
Pros and Cons of Hutchison China MediTech Ltd ADR in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Hutchison China MediTech Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Hutchison China MediTech Ltd ADR | 0.000% | 3.390% | 0.000% | -11.594% | 11.927% | -10.949% | -47.863% |
| China Traditional Chinese Medicine Co Ltd | 0.000% | 0.980% | -2.830% | -8.850% | -5.505% | -60.385% | -58.130% |
| China Resources Pharmaceutical Group Ltd | 0.400% | 4.167% | 2.881% | -21.875% | 5.042% | -41.520% | -18.699% |
| Repligen Corp. | 4.180% | -1.429% | -10.239% | -26.054% | -26.553% | -35.271% | -37.112% |
Comments
HUTCHMED (HCM) had its price target lowered by Bank of America Corporation from $21.00 to $20.00. They now have a "buy" rating on the stock.
Show more
Ratings data for HCM provided by MarketBeat
HUTCHMED (NASDAQ:HCM) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for HCM provided by MarketBeat
HUTCHMED (NASDAQ:HCM) was downgraded by analysts at Morgan Stanley from an "equal weight" rating to an "underweight" rating. They now have a $13.75 price target on the stock.
Show more
Ratings data for HCM provided by MarketBeat